| Date Filed | Type | Description |
| 10/13/2023 |
S-1/A
| Form S-1/A - General form for registration of securities under the Securities Act of 1933: [Amend] |
| 10/11/2023 |
8-K/A
| Quarterly results |
| 10/11/2023 |
8-K
| Quarterly results |
| 09/28/2023 |
8-K
| Quarterly results |
| 07/27/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/14/2023 |
8-K
| Quarterly results |
| 05/10/2023 |
8-K
| Investor presentation |
| 04/13/2023 |
8-K
| Quarterly results |
| 02/24/2023 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 02/24/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/31/2023 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 01/06/2023 |
8-K
| Investor presentation |
| 12/30/2022 |
8-K
| Quarterly results |
| 12/23/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 12/23/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 11/14/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 10/07/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 09/16/2022 |
8-K
| Submission of Matters to a Vote of Security Holders Interactive Data |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 07/22/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/22/2022 |
8-K
| Quarterly results |
| 07/13/2022 |
10-K
| Annual Report for the period ended March 31, 2022 |
| 06/29/2022 |
NT 10-K
| Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405: |
| 02/11/2022 |
10-Q
| Quarterly Report for the period ended December 31, 2021 |
| 01/20/2022 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data|
Docs:
|
"[Certain identified information has been excluded from the exhibit because it is both not material and would be competitively harmful if publicly disclosed.] Non-Exclusive Distribution and Supply Agreement This Non-Exclusive Distribution and Supply Agreement is entered into as of January 19, 2022 by and between Sonoma Pharmaceuticals, Inc., a Delaware corporation having a place of business at 645 Molly Ln, Suite 150, Woodstock, GA 30189 and Salus Medical, LLC a Limited Liability Company, having a place of business at 2202 W Lone Cactus Dr #15, Phoenix, AZ 85027 . Whereas, Supplier manufactures certain products based on the Proprietary Rights and subject to the Label Claims as approved by the Government Authorities, which it is willing to supply to Distributor on the terms and subject to th...",
"[Certain identified information has been excluded from the exhibit because it is both not material and would be competitively harmful if publicly disclosed.]" |
|
| 01/14/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 01/13/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 01/06/2022 |
8-K
| Investor presentation |
| 11/15/2021 |
10-Q
| Quarterly Report for the period ended September 30, 2021 |
| 11/09/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
| 09/21/2021 |
8-K
| Quarterly results |
| 09/03/2021 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
| 09/03/2021 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
| 08/30/2021 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
|